University of Kentucky Research Foundation

Luke H Bradley

Don Marshall Gash

Greg A Gerhardt

Raymond T Bartus

Therapeutic peptides of the following sequence are disclosed: Xaa-Xaa-Xaa-Xaa-Xaa, and optionally further comprising Xaa, wherein Xaa represents an amino acid; Xaais proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.

Anti-neurodegenerative therapeutic, method of manufacture, and use

The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or 'Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)'), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Amidated dopamine neuron stimulating peptides for CNS dopaminergic upregulation

The present invention relates to the use of novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or 'Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)'), for treating brain diseases and injuries that result in dopaminergic deficiencies and mitochodrial dysfunction, e.g., reduced complex I enzyme activity.

Growing community of inventors

Lexington, KY, United States of America

Luke H Bradley